186 related articles for article (PubMed ID: 25407157)
1. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.
Salzer WL; Jones TL; Devidas M; Dreyer ZE; Gore L; Winick NJ; Sung L; Raetz E; Loh ML; Wang CY; De Lorenzo P; Valsecchi MG; Pieters R; Carroll WL; Hunger SP; Hilden JM; Brown P
Pediatr Blood Cancer; 2015 Mar; 62(3):414-8. PubMed ID: 25407157
[TBL] [Abstract][Full Text] [Related]
2. Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407.
Salzer WL; Jones TL; Devidas M; Hilden JM; Winick N; Hunger S; Carroll WL; Camitta B; Dreyer ZE
Pediatr Blood Cancer; 2012 Nov; 59(5):834-9. PubMed ID: 22488662
[TBL] [Abstract][Full Text] [Related]
3. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).
Dreyer ZE; Hilden JM; Jones TL; Devidas M; Winick NJ; Willman CL; Harvey RC; Chen IM; Behm FG; Pullen J; Wood BL; Carroll AJ; Heerema NA; Felix CA; Robinson B; Reaman GH; Salzer WL; Hunger SP; Carroll WL; Camitta BM
Pediatr Blood Cancer; 2015 Mar; 62(3):419-26. PubMed ID: 25399948
[TBL] [Abstract][Full Text] [Related]
4. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
Miller TP; Getz KD; Li Y; Demissei BG; Adamson PC; Alonzo TA; Burrows E; Cao L; Castellino SM; Daves MH; Fisher BT; Gerbing R; Grundmeier RW; Krause EM; Lee J; Lupo PJ; Rabin KR; Ramos M; Scheurer ME; Wilkes JJ; Winestone LE; Hawkins DS; Gramatges MM; Aplenc R
Lancet Haematol; 2022 Sep; 9(9):e678-e688. PubMed ID: 35870472
[TBL] [Abstract][Full Text] [Related]
5. Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the Children's Cancer Group Protocol 1953: a report from the Children's Oncology Group.
Salzer W; Dinndorf P; Dreyer Z; Hilden J; Reaman GH
J Pediatr Hematol Oncol; 2009 Jun; 31(6):398-405. PubMed ID: 19648788
[TBL] [Abstract][Full Text] [Related]
6. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X.
Wheeler K; Chessells JM; Bailey CC; Richards SM
Arch Dis Child; 1996 Feb; 74(2):101-7. PubMed ID: 8660070
[TBL] [Abstract][Full Text] [Related]
7. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.
Silverman LB; McLean TW; Gelber RD; Donnelly MJ; Gilliland DG; Tarbell NJ; Sallan SE
Cancer; 1997 Dec; 80(12):2285-95. PubMed ID: 9404706
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
9. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study.
Lauer SJ; Camitta BM; Leventhal BG; Mahoney D; Shuster JJ; Kiefer G; Pullen J; Steuber CP; Carroll AJ; Kamen B
J Pediatr Hematol Oncol; 1998; 20(3):229-33. PubMed ID: 9628434
[TBL] [Abstract][Full Text] [Related]
10. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
Slayton WB; Schultz KR; Kairalla JA; Devidas M; Mi X; Pulsipher MA; Chang BH; Mullighan C; Iacobucci I; Silverman LB; Borowitz MJ; Carroll AJ; Heerema NA; Gastier-Foster JM; Wood BL; Mizrahy SL; Merchant T; Brown VI; Sieger L; Siegel MJ; Raetz EA; Winick NJ; Loh ML; Carroll WL; Hunger SP
J Clin Oncol; 2018 Aug; 36(22):2306-2314. PubMed ID: 29812996
[TBL] [Abstract][Full Text] [Related]
12. [Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003-2007].
Arteaga-Ortiz L; Buitrón-Santiago N; Rosas-López A; Rosas-Arzate G; Armengolt-Jiménez A; Aguayo A; López-Karpovitch X; Crespo-Solís E
Rev Invest Clin; 2008; 60(6):459-69. PubMed ID: 19378832
[TBL] [Abstract][Full Text] [Related]
13. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
Sulis ML; Blonquist TM; Stevenson KE; Hunt SK; Kay-Green S; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JG; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 May; 65(5):e26952. PubMed ID: 29319209
[TBL] [Abstract][Full Text] [Related]
15. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999.
Chessells JM; Harrison CJ; Watson SL; Vora AJ; Richards SM;
Br J Haematol; 2002 May; 117(2):306-14. PubMed ID: 11972512
[TBL] [Abstract][Full Text] [Related]
16. Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG).
Tanimoto M; Miyawaki S; Ino T; Kyo T; Sakamaki H; Naoe T; Hiraoka A; Asou N; Ohshima T; Tsubaki K; Kuriyama K; Ueda T; Minamil S; Okabe K; Saito H; Murakami H; Hirano M; Dohy H; Onozawa Y; Suzuki H; Ohno R
Int J Hematol; 1998 Dec; 68(4):421-9. PubMed ID: 9885441
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia].
Pan C; Gu LJ; Xue HL; Chen J; Dong L; Zhou M; Luo CY; Wang YP; Tang JY
Zhonghua Er Ke Za Zhi; 2007 May; 45(5):324-8. PubMed ID: 17697614
[TBL] [Abstract][Full Text] [Related]
18. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
[TBL] [Abstract][Full Text] [Related]
19. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
Rahman AT; Gupta SK; Mannan MA; Nahar K
Kathmandu Univ Med J (KUMJ); 2012; 10(40):53-9. PubMed ID: 23575054
[TBL] [Abstract][Full Text] [Related]
20. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
